Lymphoma & Myeloma: An International Congress on Hematologic Malignancies 2017
In-Person Event
Oct 26 - 28, 2017
New York City, New York, USA
OVERVIEW
Lymphoma & Myeloma: An International Congress on Hematologic Malignancies is organized by Imedex and would be held during Oct 26 - 28, 2017 at Sheraton New York Times Square Hotel, New York, United States Of America.
The target audience for this medical event for oncologists, hematologists. This CME Conference has been approved with a maximum of 21.0 AMA PRA Category 1 Credits.
Conference Objectives are :
Upon successful completion of these educational activities, participants should be better able to:
• Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignancies.
• Define mechanisms of action of current and emerging agents for hematologic malignancies.
• Assess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignancies.
• Formulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, whose with poor functional capacity).
• Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignancies.
• Evaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignancies.
Additional details will be posted as soon as they are available.
The target audience for this medical event for oncologists, hematologists. This CME Conference has been approved with a maximum of 21.0 AMA PRA Category 1 Credits.
Conference Objectives are :
Upon successful completion of these educational activities, participants should be better able to:
• Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignancies.
• Define mechanisms of action of current and emerging agents for hematologic malignancies.
• Assess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignancies.
• Formulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, whose with poor functional capacity).
• Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignancies.
• Evaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignancies.
Additional details will be posted as soon as they are available.
KEY DATES
26 Oct, 2017
Event Start Date
28 Oct, 2017
Event End Date
SPECIALITIES
OncologyHematology Blood and Marrow TransplantSUGGESTED HOTELS
CONFERENCE VENUE
Sheraton New York Times Square HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links